Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and meta-analysis

Abstract Background Smoking impairs lung immune function and damages upper airways, increasing risks of contracting and severity of infectious diseases. This paper quantifies the association between smoking and COVID-19 disease progression. Methods We searched PubMed and Embase for studies published...

Бүрэн тодорхойлолт

-д хадгалсан:
Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид: Roengrudee Patanavanich (Зохиогч), Stanton A. Glantz (Зохиогч)
Формат: Ном
Хэвлэсэн: BMC, 2021-08-01T00:00:00Z.
Нөхцлүүд:
Онлайн хандалт:Connect to this object online.
Шошгууд: Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d21c5aafa2c14fed97c5ed20ae8d1c20
042 |a dc 
100 1 0 |a Roengrudee Patanavanich  |e author 
700 1 0 |a Stanton A. Glantz  |e author 
245 0 0 |a Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and meta-analysis 
260 |b BMC,   |c 2021-08-01T00:00:00Z. 
500 |a 10.1186/s12889-021-11579-x 
500 |a 1471-2458 
520 |a Abstract Background Smoking impairs lung immune function and damages upper airways, increasing risks of contracting and severity of infectious diseases. This paper quantifies the association between smoking and COVID-19 disease progression. Methods We searched PubMed and Embase for studies published from January 1-May 25, 2020. We included studies reporting smoking behavior of COVID-19 patients and progression of disease, including death. We used random effects meta-analysis, meta-regression and locally weighted regression and smoothing to examine relationships in the data. Results We identified 46 peer-reviewed papers with a total of 22,939 COVID-19 patients, 5421 (23.6%) experienced disease progression and 2914 (12.7%) with a history of smoking (current and former smokers). Among those with a history of smoking, 33.5% experienced disease progression, compared with 21.9% of non-smokers. The meta-analysis confirmed an association between ever smoking and COVID-19 progression (OR 1.59, 95% CI 1.33-1.89, p = 0.001). Ever smoking was associated with increased risk of death from COVID-19 (OR 1.19, 95% CI 1.02-1.39, p = 0.003). We found no significant difference (p = 0.864) between the effects of ever smoking on COVID-19 disease progression between adjusted and unadjusted analyses, suggesting that smoking is an independent risk factor for COVID-19 disease progression. We also found the risk of having COVID-19 progression higher among younger adults (p = 0.001), with the effect most pronounced among younger adults under about 45 years old. Conclusions Smoking is an independent risk for having progression of COVID-19, including mortality. The effects seem to be higher among young people. Smoking prevention and cessation should remain a priority for the public, physicians, and public health professionals during the COVID-19 pandemic. 
546 |a EN 
690 |a COVID-19 
690 |a Coronavirus 
690 |a Meta-analysis 
690 |a Disease progression 
690 |a Odds ratio 
690 |a Death 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n BMC Public Health, Vol 21, Iss 1, Pp 1-9 (2021) 
787 0 |n https://doi.org/10.1186/s12889-021-11579-x 
787 0 |n https://doaj.org/toc/1471-2458 
856 4 1 |u https://doaj.org/article/d21c5aafa2c14fed97c5ed20ae8d1c20  |z Connect to this object online.